A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2019
Price : $35 *
At a glance
- Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Nivolumab (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 29 Jul 2019 Status changed from not yet recruiting to recruiting.
- 21 Dec 2018 Planned initiation date changed from 1 Jan 2019 to 31 Jan 2019.
- 28 Nov 2018 New trial record